Genomics in Focus: Oncology

Approximately 5-10% of all cancers are thought to have a genetic basis. Genetic testing in oncology can influence treatment options for those diagnosed with cancer and guide the management of future cancer risk. Genetic diagnosis of relatives also provides an opportunity for risk reduction and early diagnosis.

Mainstreaming is the process whereby cancer genetic testing is ordered through Medicare by oncologists and surgeons. Drawing on experience of mainstreaming from the gynae-oncology setting, Dr Michelle Harrison provides her perspective on mainstream genetic testing. Register now to learn more about;

- Relevance of genetic testing for oncology

- Types of genetic tests available and possible results

- Patients who may benefit and Medicare eligibility

- Practicalities of ordering tests

- Consent and other considerations

Guest Speaker
Dr Michelle Harrison is a senior staff specialist at Chris O’Brien Lifehouse in Sydney. She specialises in gynaecological cancers with a special interest in the management of rare cancers. She has been involved in the development of mainstream genetic testing in Australia for gynaecological cancer. She is the current Chair of the ANZGOG ASM organising committee. She is a dedicated clinician, loves teaching and when not working can usually be found exercising.

Register here: https://www.eventbrite.com.au/e/genomics-in-focus-oncology-tickets-736930016517?aff=oddtdtcreator